

COOPER & DUNHAM LLP
ATTORNEYS AT LAW1185 AVENUE OF THE AMERICAS, NEW YORK, NEW YORK 10036
TELEPHONE: (212) 278-0400**RECEIVED**
CENTRAL FAX CENTER
MAY 27 2008IVAN S. KAVRUKOV
PETER O. MURRAY
WILLIAM E. PELTON
ROBERT D. KATZ
PAUL TENG
WENDY E. MILLER
PETER J. PHILLIPS
RICHARD P. JAWORSKI
BRIAN J. AMOS
GREGORY J. CARBO
MICHAEL UN*
JENNIFER RAKNORMAN H. ZWIN
JOHN P. WHITE
ROBERT B.G. HOROWITZ
ERIC D. KIRSCH
GARY J. GERSHIK
ROBERT T. MALDONADO
RICHARD S. MILNER
AUDE GERSPACHER
TONIA A. SAYOUR
HINDY R. DYM
LETTIA A. DEGRASSE*FACSIMILE: (212) 391-0525
(212) 391-0526
(212) 391-0630
(212) 391-0631
(212) 827-0247OF COUNSEL
CHRISTOPHER C. DUNHAMSCIENTIFIC ADVISOR
JAMES R. MAJOR, D. PHIL.
PAMELA J. SAVAGE, PH.D.
JACK ROSA, PH.D.REGISTERED PATENT AGENT
ANDREW CHUNG, B.E.FOUNDED 1887
www.cooperdunham.com

*NEW YORK STATE BAR ADMISSION PENDING

FACSIMILE TRANSMISSION**PLEASE DELIVER THE FOLLOWING PAGES**

TO : USPTO Central Facsimile Number

AT : United States Patent and Trademark Office

FACSIMILE NO. : (571) 273-8300

FROM : Gary J. Gershik / JRM

DATE : May 27, 2008

TOTAL NUMBER OF PAGES, INCLUDING COVER SHEET: Fifty (50)

IF YOU DO NOT RECEIVE ALL THE PAGES, PLEASE CALL BACK AS SOON AS POSSIBLE TO (212) 278-0400.

Supplemental Information Disclosure Statement in connection with U.S. Serial No. 10/693,367, filed October 24, 2003, on behalf of Audrey Minden, entitled PAK4-RELATED ANTIBODIES, including Exhibit A (Form PTO-1449 (Substitute)), Exhibit B (copy of April 1, 2005 Final Office Action), Exhibits 1 to 3 (copies of cited references), and a Facsimile Certificate of Transmission dated May 27, 2008.

Our Docket 0575/55311-AZ-PCT-US/JPW/GJG/JRM

THE INFORMATION CONTAINED IN THIS FACSIMILE TRANSMISSION IS INTENDED SOLELY FOR THE PERSONAL AND CONFIDENTIAL USE OF THE DESIGNATED RECIPIENT(S) NAMED ABOVE. THIS TRANSMISSION MAY BE AN ATTORNEY-CLIENT COMMUNICATION CONTAINING INFORMATION THAT IS PRIVILEGED AND CONFIDENTIAL. IF THE READER OF THIS MESSAGE IS NOT A DESIGNATED RECIPIENT OR AN AGENT RESPONSIBLE FOR DELIVERING IT TO A DESIGNATED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT YOU HAVE RECEIVED THIS DOCUMENT IN ERROR, AND THAT ANY REVIEW, DISTRIBUTION, OR COPYING OF THIS MESSAGE IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, OR IF UPON READING THIS DOCUMENT YOU HAVE REASON TO BELIEVE THAT THE DOCUMENT WAS INADVERTENTLY SENT TO YOU, PLEASE NOTIFY US IMMEDIATELY BY COLLECT TELEPHONE CALL AND RETURN THE ORIGINAL MESSAGE TO US BY MAIL. THANK YOU.

Dkt. 0575/55311-AZ-PCT-US/JPW/GJG/JRM

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
CENTRAL FAX CENTER

MAY 27 2008

Applicant : Audrey Minden

Serial No. : 10/693,367

Examiner : Szperka, M.E.

Filed : October 24, 2003

Art Unit : 1644

For : PAK4-RELATED ANTIBODIES

1185 Avenue of the Americas
New York, New York 10036
May 27, 2008

BY FACSIMILE - (571) 273-8300

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, applicant directs the Examiner's attention to the following references which are listed on the Form PTO-1449 (Substitute) attached hereto as Exhibit A and certain of which are attached hereto as Exhibits 1 to 3:

1. U.S. Patent No. 6,656,716 B1, issued December 2, 2003 to Gregory Plowman et al.;
2. U.S. Patent No. 6,680,170 B2, issued January 20, 2004 to Gregory Plowman et al.;
3. U.S. Patent Application Publication No. 2004/0224323 A1, published November 11, 2004 (Gregory Plowman et al.);

05/27/2008 HMARZI1 00000052 033125 10693367

01 FC:1806 180.00 DA

Applicant : Audrey Minden
Serial No. : 10/693,367
Filed : October 24, 2003
Page 2 of 4 of May 27, 2008 Supplemental Information Disclosure Statement

4. U.S. Patent No. 6,667,168 B1, issued December 23, 2003 to Audrey Minden;
5. Notification of Transmittal of the International Search Report or the Declaration, including International Search Report mailed November 5, 1999 in connection with PCT International Application No. PCT/US99/11341, filed May 21, 1999 (Exhibit 1);
6. Written Opinion mailed July 25, 2000 in connection with PCT International Application No. PCT/US99/11341, filed May 21, 1999 (Exhibit 2); and
7. Notification of Transmittal of International Preliminary Examination Report, including International Preliminary Examination Report mailed November 7, 2000 in connection with PCT International Application No. PCT/US99/11341, filed May 21, 1999 (Exhibit 3).

The Examiner is respectfully requested to make each of these references of record in the present application by initialing and returning a copy of the enclosed substitute Form PTO-1449.

Copies of items 1 to 4, all U.S. Patents or U.S. Patent Application Publications, have not been included as Exhibits in accordance with 37 C.F.R. § 1.98(a)(2)(ii).

Applicant listed items 1 to 3 in an April 7, 2005 Supplemental Information Disclosure Statement in connection with the subject application. Pursuant to 37 C.F.R. § 1.97(c), applicant included

RECEIVED
CENTRAL FAX CENTER

MAY 27 2008

Applicant : Audrey Minden
Serial No. : 10/693,367
Filed : October 24, 2003
Page 3 of 4 of May 27, 2008 Supplemental Information Disclosure
Statement

the fee under 37 C.F.R. § 1.17(p) with the April 1, 2005 Supplemental Information Disclosure Statement. The United States Patent and Trademark Office issued an April 1, 2005 Final Office Action in connection with the subject application, a copy of which is attached hereto as Exhibit B. However, the undersigned's office did not receive a copy of the April 1, 2005 Final Office Action until August 10, 2005.

Applicant notes that item 4 issued from the parent application of the subject application.

Applicant notes that items 5 to 7 were issued in connection with PCT International Application No. PCT/US99/11341, filed May 21, 1999. Applicant further notes that the subject application is a divisional of a continuation application of PCT International Application No. PCT/US99/11341.

According to 37 C.F.R. § 1.97(d), an Information Disclosure Statement filed after the period specified in 37 C.F.R. § 1.97(c) shall be considered if accompanied by the fee set forth in 37 C.F.R. § 1.17(p) or a statement under 37 C.F.R. § 1.97(e). The required fee set forth in 37 C.F.R. § 1.17(p) is one hundred and eighty dollars (\$180.00) and authorization is hereby given to charge the amount of this fee to Deposit Account No. 03-3125.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicant's undersigned attorney invites the Examiner to telephone him at the number provided below.


RECEIVED
CENTRAL FAX CENTER

MAY 27 2008

Applicant : Audrey Minden
Serial No. : 10/693,367
Filed : October 24, 2003
Page 4 of 4 of May 27, 2008 Supplemental Information Disclosure
Statement

No fee, other than the authorized fee of \$180.00, is deemed necessary in connection with the filing of this Supplemental Information Disclosure Statement. However, if any fee is required authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,



John P. White
Registration No. 28,678
Gary J. Gershik
Registration No. 39,992
Attorneys for Applicant
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

I hereby certify that this
correspondence is being transmitted
on this date by facsimile to:

Central Patent Fax No. (571) 273-8300

And is addressed to:

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


 05/27/08
James R. Major Date

EXHIBIT A